On June 3, 2025 PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), reported that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (Press release, The Ohio State University Comprehensive Cancer Center, JUN 3, 2025, View Source;james-cancer-hospital-and-solove-research-institute-302471800.html [SID1234653688]). This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pursuant to the agreement Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor.
The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record (EHR) integration; initiation of a large clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a large clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. It also calls for close collaboration on the development of clinical cancer care pathways, platform software enhancements, and best practices for clinical use of the implantable physiological monitor.
"We are thrilled to advance our strategic partnership with OSUCCC – James, one of the largest and most prestigious academic cancer centers in the nation, following the successful completion of a pilot program demonstrating the strong clinical utility of our platform," said Brian deGuzman, M.D., Chief Operating Officer of Veris Health. "This commercial transition represents a major milestone for Veris. We look forward to working closely with the OSUCCC – James team to enhance the care of thousands of cancer patients there every year."
"At the OSUCCC – James, delivering personalized, world-class cancer care remains our top priority," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chair of Gynecologic Oncology at The James Cancer Hospital and Solove Research Institute. "After a successful pilot program, we are excited to be entering into a long-term strategic partnership with Veris Health to expand access to the Veris Cancer Care Platform and enhance the care of our patients."
The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.
Cancer patients enrolled on the platform receive a VerisBox of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance.
Cancer centers and oncology practices interested in learning more about Veris and the Veris Platform, please visit www.verishealth.com to contact a company representative.